Related references
Note: Only part of the references are listed.Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease
Einat Ritter et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2021)
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
Sare Verstockt et al.
INFLAMMATORY BOWEL DISEASES (2021)
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab
Brigida Barberio et al.
INFLAMMATORY BOWEL DISEASES (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients
Lorenzo Bertani et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe
Alessandro Armuzzi et al.
PLOS ONE (2020)
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
Maria Chaparro et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment
Lorenzo Bertani et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio
Lorenzo Bertani et al.
INFLAMMATORY BOWEL DISEASES (2020)
Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice
Renske Wilhelmina Maria Pauwels et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies
Lorenzo Bertani et al.
Clinical and Translational Gastroenterology (2020)
Serum Interleukin-6 and-8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
Lorenzo Bertani et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
Lorenzo Bertani et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohnʼs Disease Than Ulcerative Colitis
Brigida Barberio et al.
Clinical and Translational Gastroenterology (2020)
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio
Lorenzo Bertani et al.
INFLAMMATORY BOWEL DISEASES (2020)
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Belen Beltran et al.
DIGESTIVE DISEASES (2019)
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
Bram Verstockt et al.
EBIOMEDICINE (2019)
Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
Claire Liefferinckx et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
Luisa Guidi et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Pieter Hindryckx et al.
JOURNAL OF CROHNS & COLITIS (2018)
Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis
Yu Nishida et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting
Maria Gloria Mumolo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Maria Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease
Raja Atreya et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease
Xavier Roblin et al.
INFLAMMATORY BOWEL DISEASES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Nathaniel R. West et al.
NATURE MEDICINE (2017)
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
Mahmoud H. Mosli et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
Maria Theresa Arias et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Disease monitoring in inflammatory bowel disease
Shannon Chang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate
Alain M. Schoepfer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
The burden of inflammatory bowel disease in Europe
Johan Burisch et al.
JOURNAL OF CROHNS & COLITIS (2013)
Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
Gary R. Lichtenstein
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab
Kotaro Ogawa et al.
JOURNAL OF CROHNS & COLITIS (2012)
Surgery for adult Crohn's disease: what is the actual risk?
Guillaume Bouguen et al.
GUT (2011)
Share Paper
